Baxter International Inc. - BAX STOCK NEWS

Baxter International Inc. (NYSE:BAX) presented new findings at the American Society of Nephrology’s Kidney Week, indicating that patients using the Sharesource remote patient management platform for automated peritoneal dialysis (APD) experienced nearly double the survival rates compared to those using conventional methods. This study, involving 815 kidney patients across 22 hospitals in Mexico, suggests that digital health solutions can significantly enhance clinical outcomes, reducing hospital visits during the COVID-19 pandemic.

Baxter International Inc. (NYSE:BAX) will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Chief Financial Officer Jay Saccaro is set to speak at 9:40 a.m. Eastern Time. Investors and the public can access the live webcast of the presentation through www.baxter.com, which will also be available for replay until May 21, 2022. Baxter continues to innovate in medical products, impacting patients and healthcare providers globally.

Baxter International reported a 9% increase in third-quarter revenue, reaching $3.2 billion, driven by strong sales across all geographic segments. U.S. GAAP earnings per share rose 29% to $0.89, while adjusted EPS increased by 23% to $1.02. Baxter anticipates full-year sales growth of 7%-8% and adjusted EPS between $3.58 and $3.62. The company announced the acquisition of Hillrom, aiming to enhance its product portfolio and innovation pipeline. Additionally, Baxter launched new medical products and received FDA approval for premix Norepinephrine Bitartrate injection.

Baxter and bioMérieux have announced the CE marking of the NEPHROCLEAR™ CCL14 Test, a diagnostic tool designed to predict persistent severe acute kidney injury (PS-AKI). Expected for commercial launch in western Europe in 2022, the test aims to optimize critical care by helping healthcare providers anticipate the appropriate level of care for AKI patients. CCL14 has been identified as the most predictive biomarker for PS-AKI, with a diagnostic accuracy (AUC) of 0.82, indicating its potential to significantly improve patient outcomes.

Baxter International Inc. (NYSE:BAX) will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8, 2021, at 8:50 a.m. ET.

The presentation by CFO Jay Saccaro will be accessible via a live webcast on www.baxter.com and available for replay until November 7, 2022. Baxter, a global leader in medical products, serves millions of patients daily across over 100 countries, focusing on critical care, nutrition, and renal products. For more information, visit their website.

Baxter International Inc. (NYSE:BAX) presented critical care study findings at the 34th Annual European Society of Intensive Care Medicine (ESICM) LIVES virtual congress from Oct. 3-6, 2021. The data emphasized personalized healthcare approaches for patients with acute kidney injury (AKI) or sepsis. A study revealed the prevalence of persistent severe AKI (PS-AKI) among hospitalized adults, significantly increasing mortality risks. Additionally, findings from the FRESH clinical trial indicated that dynamic fluid management may improve kidney function in septic patients. Baxter also organized symposia on digital transformation and fluid management.

Baxter International Inc. (NYSE:BAX) will host a conference call on October 28, 2021, at 7:30 a.m. Central Time to discuss its third-quarter 2021 financial results. Participants can pre-register using the provided link or access the call via webcast on Baxter's website. With over 85 years in the industry, Baxter continues to offer critical care, nutrition, and surgical products globally. The meeting underscores Baxter's commitment to transparency and investor communication as it prepares to share key financial insights.

Baxter International Inc. (NYSE:BAX) has received FDA approval for its premix Norepinephrine Bitartrate in 5% Dextrose Injection, the first ready-to-use formulation of norepinephrine, which is crucial for treating severe hypotension in adults. Available in 4 mg/250 mL and 8 mg/250 mL concentrations, this formulation enhances patient safety by reducing compounding errors and offers flexible storage options, including room temperature. The product features a shelf life of up to 21 months in refrigeration and up to 90 days at room temperature, utilizing Baxter's proprietary VIAFLO container technology.

Baxter International has announced its acquisition of Hillrom for $156.00 per share, totaling $10.5 billion in cash. This strategic move aims to enhance access to care and accelerate digital health solutions globally. The acquisition is expected to generate approximately $250 million in annual pre-tax cost synergies by year three, with a positive impact on Baxter's adjusted earnings per share (EPS) projected to exceed 20% by year three. Both companies' boards have unanimously approved the deal, which is set to close by early 2022.